

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5022349

| | |
|---|-------------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| STÉPHANIE GARCIA | 06/20/2018 |
| RECEIVING PARTY DATA | |
| Name: | THERACHON |
| Street Address: | 2000 ROUTE DES LUCIOLES |
| Internal Address: | LES ALGORITHMES - ARISTOTE A |
| City: | BIOT |
| State/Country: | FRANCE |
| Postal Code: | 06410 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 15943436 |
| CORRESPONDENCE DATA | |
| Fax Number: | (617)428-7045 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | (617) 428-0200 |
| Email: | patentadministrator@clarkelbing.com |
| Correspondent Name: | CLARK & ELBING LLP |
| Address Line 1: | 101 FEDERAL STREET |
| Address Line 2: | 15TH FLOOR |
| Address Line 4: | BOSTON, MASSACHUSETTS 02110 |
| ATTORNEY DOCKET NUMBER: | 51088-006003 |
| NAME OF SUBMITTER: | TODD ARMSTRONG, PH.D. |
| SIGNATURE: | /Todd Armstrong, Ph.D./ |
| DATE SIGNED: | 06/25/2018 |
| Total Attachments: 3 | |
| source=51088-006WO3 - Executed Assignment (Garcia --_ TherAchon)#page1.tif | |
| source=51088-006WO3 - Executed Assignment (Garcia --_ TherAchon)#page2.tif | |
| source=51088-006WO3 - Executed Assignment (Garcia --_ TherAchon)#page3.tif | |

ASSIGNMENT

For valuable consideration, I,

| Full Name of Assignor | City | State (and Country if not USA) |
|-----------------------|------|--------------------------------|
| Stéphanie Garcia | Nice | France |

hereby assign to

| Full Name of Assignee | Business Address |
|-----------------------|---|
| TherAchon | 2000 route des lucioles, Les Algorithmes – Aristote A Biot, FR 06410 |

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more applications for United States Patent signed by me, identified as:

| Title of Application | Filing Date | Serial Number |
|--|--------------|-------------------|
| SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES AND USES THEREOF | July 7, 2017 | PCT/EP2017/067119 |

and I authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting above the filing date and serial number of said application when known; this assignment includes said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and I authorize the Assignee to apply in all countries in my name or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and I agree for me and my respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.

ASSIGNOR:



Stéphanie Garcia

20th June 2018

Date

Witness:



Signature

20th June 2018


Date

VINCENT SARRAZ

Printed name

ASSIGNEE:

For **Therachon:**



Luca Santarelli
Chief Executive Officer

June 20 2018
Date



Richard Porter
Chief Operating Officer

June 20 2018
Date

Witness:

Signature

Date

Printed name